Triphase said it is also evaluating an oral formulation of marizomib in IND-enabling studies. Marizomib has received orphan drug designation from the FDA and the EU as a multiple myeloma treatment.

Triphase Accelerator was spun out of the Ontario Institute for Cancer Research (OICR), with support from the Fight Against Cancer Innovation Trust (FACIT), MaRS Innovation and MaRS.

Celgene now has full responsibility for the FDA orphan-tagged marizomib, and will pay the Toronto and San Diego-based Triphase to complete an ongoing Phase I relapsed refractory multiple myeloma ...

Catalent and Triphase Accelerator Corporation have announced that Triphase will obtain worldwide rights to further develop Catalent's proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been ...

Celgene will pay $40 million up front for an option to acquire Triphase Accelerator’s small molecule targeting WDR5 protein, a key player in the formation of protein complexes that indirectly ...

Meaningful progress in developing triphase catalytic reactions that minimize hazardous waste and are economically viable will, in my view, require close collaboration among organic chemists ...